Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Suzuken Co ( (JP:9987) ) just unveiled an announcement.
Suzuken Co., Ltd. has revised its full-year consolidated financial results forecast for the fiscal year ended March 31, 2025. The revision reflects an increase in net sales driven by new drugs and COVID-19-related products, leading to higher operating and net income than previously anticipated. This adjustment indicates a positive impact on Suzuken’s financial performance and suggests strengthened market positioning due to effective cost management and strategic product offerings.
More about Suzuken Co
Suzuken Co., Ltd. operates in the pharmaceutical industry, focusing on the distribution of pharmaceutical products, including specialty drugs and COVID-19-related products. The company is listed on the Prime Markets of the Tokyo and Nagoya Stock Exchanges, as well as the Sapporo Securities Exchange.
YTD Price Performance: 20.58%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.02B
Find detailed analytics on 9987 stock on TipRanks’ Stock Analysis page.